Rezulin®,
the brand name for the generic drug troglitazone, was manufactured
by Parke-Davis, a division of Warner-Lambert Company. Rezulin®
first came on the market in the United States in March, 1997, after
receiving "fast track" approval from the United States
Food and Drug Administration (FDA) as a treatment for patients suffering
from Type II diabetes, which is also known as non-insulin dependent
diabetes (NIDD) or adult onset diabetes mellitus (AODM).
In March, 2000, by which
time approximately one-million diabetics in the United States had
been treated with Rezulin®, the drug was removed from the market
by the FDA after determining that severe liver toxicity was associated
with its use. In fact, many cases of liver failure, including as
many as 90 deaths, had been reported to the FDA as of the time Rezulin®
was taken off the market.
Symptoms in the early
stages of liver damage may be difficult to detect. Symptoms that
may manifest in advanced stages include yellow eyes, abdominal pain,
nausea, clay-colored stools, and dark urine. Severe liver damage
caused by Rezulin® may result in death or necessitate a liver
transplant.
Currently there are many
individual and class-action lawsuits pending against Parke-Davis
and Warner-Lambert nationwide. The individual suits seek compensatory
and punitive damages against the defendant manufacturers for negligence,
strict liability, breach of warranty and/or fraud based on the allegation
that the claimants (or claimants' decedents) who used Rezulin®
suffered severe liver damage or death as a result of taking the
drug. The pending class action suits seek an agreement from the
manufacturers to pay the costs of the medical monitoring necessary
to detect latent liver and/or cardiac damage in those individuals
who took Rezulin®.
Preserving
Your Claim
All states have mandatory time limits in which lawsuits must be
filed or claims may be forever barred. Persons believing they may
have been injured by a recalled or dangerous drug and desiring to
have a lawyer review their case may complete our online
form.
|
